首页> 外文期刊>American journal of medical genetics, Part A >Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader-Willi syndrome: An observational study
【24h】

Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader-Willi syndrome: An observational study

机译:睾丸替代疗法可改善成年男性普拉德-威利综合症患者的继发性特征和身体组成,而无不良行为问题:一项观察性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Prader-Willi syndrome (PWS), a complex genetic disorder, arises from suppressed expression of paternally inherited imprinted genes on chromosome 15q11-q13. Characteristics include short stature, intellectual disability, behavioral problems, hypogonadism, obesity, and reduced bone and muscle mass. Testosterone replacement (TR) remains controversial due to concerns regarding behavioral problems. To evaluate the effects of TR on secondary sexual characteristics, body composition, and behavior in adult males with PWS, 22 male PWS patients over the age of 16 with behavioral scores of less than grade 4 on the Modified Overt Aggression Scale (MOAS) underwent monthly intramuscular TR (125mg). Pubertal change, body composition and behavior were evaluated before and after 24 months of therapy. Serum testosterone, LH, and FSH did not change. Increased pubic hair was observed in 16 of 22 patients (72.7%). Percent body fat decreased from 47.55±2.06% to 39.75±1.60% (n=18) (P=0.018). Bone mineral density increased from 0.8505±0.0426g/cm2 to 0.9035±0.0465g/cm2 (n=18) (P=0.036), and lean body mass increased from 18093.4±863.0g to 20312.1±1027.2g (n=18) (P=0.009). The MOAS was unchanged, from 4.5±2.0 at the beginning of the study to 3.0±1.7 at the end of study indicating no increase in aggression. No behavioral problems were observed. Based on this pilot study, TR with 125mg monthly is a potentially safe and useful intervention for adult males with PWS.
机译:Prader-Willi综合征(PWS)是一种复杂的遗传疾病,是由于15q11-q13染色体上父本遗传的印迹基因表达受到抑制而引起的。特征包括身材矮小,智障,行为问题,性腺功能低下,肥胖以及骨骼和肌肉质量降低。由于对行为问题的担忧,睾丸激素替代疗法(TR)仍然引起争议。为了评估TR对成年男性PWS的继发性特征,身体成分和行为的影响,每月对22名年龄在16岁以上且行为得分低于4级的男性PWS患者进行改良公开攻击量表(MOAS)的评估肌内TR(125mg)。在治疗24个月之前和之后评估青春期变化,身体组成和行为。血清睾丸激素,LH和FSH不变。 22名患者中有16名(72.7%)观察到耻骨毛增多。体脂百分比从47.55±2.06%降至39.75±1.60%(n = 18)(P = 0.018)。骨矿物质密度从0.8505±0.0426g / cm2增加到0.9035±0.0465g / cm2(n = 18)(P = 0.036),瘦体重从18093.4±863.0g增加到20312.1±1027.2g(n = 18)( P = 0.009)。 MOAS不变,从研究开始时的4.5±2.0到研究结束时的3.0±1.7,表明攻击力没有增加。没有观察到行为问题。根据该初步研究,每月125 mg的TR对于成年男性PWS是一种潜在的安全和有用的干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号